Defined Extracellular Matrix for Stem Cell-Derived Islet Clusters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating insulin-producing beta cells for diabetes treatment, such as islet transplantation, face challenges including limited availability of cadaveric donor islets and long-term graft attrition, leading to declining insulin independence rates in patients.
Innovation Solution
A method involving the use of stem cells, serum-free media, and defined extracellular matrix proteins to generate islet-like clusters containing insulin-producing beta cells, which can be administered therapeutically to restore glucose-responsive insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cadaveric donor islets are used for transplantation, then insulin independence can be achieved in the short term, but long-term graft attrition occurs leading to declining insulin independence rates
Solution Approach 1:
The patent creates artificial islet-like clusters that copy the functional characteristics of natural pancreatic islets. These clusters are generated from stem cells and contain insulin-producing beta cells that mimic the physiological response to blood glucose changes, providing a renewable source that avoids the attrition problems of cadaveric donor islets
Solution Approach 2:
The patent employs defined extracellular matrix proteins with specific compositions and concentrations to control stem cell differentiation. By optimizing parameters such as matrix protein types (e.g., laminin, collagen), concentrations, and combination ratios, the patent achieves high-yield generation of functional beta cells with improved long-term survival characteristics
2Productivity
If cadaveric donor islets are used for transplantation, then treatment can be provided, but limited availability of donor islets hampers widespread application
Solution Approach 1:
The patent uses stem cells as a renewable template to copy and produce islet-like clusters in large quantities. This approach transforms the limited supply problem into an on-demand production system where clusters can be generated continuously from a single stem cell source
Solution Approach 2:
The patent develops a universal stem cell-based platform that can produce islet-like clusters applicable to multiple patients. The defined extracellular matrix system serves as a universal culture condition that works across different stem cell sources, enabling scalable production for widespread clinical application
3Ease of manufacture
If undefined matrix or animal-derived matrix is used for stem cell culture, then cell growth may be supported, but clinical translation and FDA approval are hindered
Solution Approach 1:
The patent transitions from undefined animal-derived matrices to precisely defined recombinant extracellular matrix proteins. The specified matrix composition includes defined concentrations of specific protein types (e.g., laminin-511, collagen-IV), eliminating batch variability and animal pathogen risks while maintaining cell growth support
Solution Approach 2:
The patent employs recombinant extracellular matrix proteins that can be produced recombinantly and used as disposable, pre-defined coating layers. This approach replaces expensive, complex animal-derived matrices with simpler, defined alternatives that are easier to validate and regulate for clinical use
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of methods and compositions for the generation of cells of endodermal lineage and beta cells and uses thereof.